Vanda Pharmaceuticals
VNDA
122 hedge funds and large institutions have $482M invested in Vanda Pharmaceuticals in 2015 Q3 according to their latest regulatory filings, with 25 funds opening new positions, 46 increasing their positions, 33 reducing their positions, and 11 closing their positions.
286% more call options, than puts
Call options by funds: $11.6M | Put options by funds: $3M
127% more first-time investments, than exits
New positions opened: 25 | Existing positions closed: 11
39% more repeat investments, than reductions
Existing positions increased: 46 | Existing positions reduced: 33
12% more funds holding
Funds holding: 109 → 122 (+13)
0% more funds holding in top 10
Funds holding in top 10: 4 → 4 (0)
10% less capital invested
Capital invested by funds: $538M → $482M (-$55.8M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
CCM
Consonance Capital Management
New York
|
+$17.6M |
| 2 |
Millennium Management
New York
|
+$8.71M |
| 3 |
ACA
Avoro Capital Advisors
New York
|
+$8.39M |
| 4 |
GPP
Great Point Partners
Greenwich,
Connecticut
|
+$3.69M |
| 5 |
Adage Capital Partners
Boston,
Massachusetts
|
+$3.36M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Goldman Sachs
New York
|
-$33M |
| 2 |
BBA
Baker Bros. Advisors
New York
|
-$5.2M |
| 3 |
AC
Armistice Capital
New York
|
-$4.67M |
| 4 |
GTC
Ghost Tree Capital
New York
|
-$4.44M |
| 5 |
JGC
J. Goldman & Co
New York
|
-$3.23M |
VNDA Hedge Fund Activity: Q3 2015 in Review
122 of the 3,590 institutional investors tracked by Wall St. Rank reported a position in Vanda Pharmaceuticals (VNDA) for Q3 2015, worth a combined $482M — down 10% from $538M a quarter earlier.
Buyers outnumbered sellers: 25 funds opened new VNDA positions and 11 closed out — a net gain of 14 holders — while 46 added to existing stakes and 33 trimmed.
The largest buyer was Consonance Capital Management, opening a new position worth an estimated $17.6M. The largest seller was Goldman Sachs, cutting an estimated $33M.
- 122 institutional investors held Vanda Pharmaceuticals (VNDA) as of Q3 2015, up from 109 in Q2 2015.
- Funds reported $482M of Vanda Pharmaceuticals stock for Q3 2015, down 10% quarter-over-quarter.
- 25 funds opened new Vanda Pharmaceuticals positions in Q3 2015 and 11 closed out, a net change of +14 holders.
- The largest Vanda Pharmaceuticals buyer in Q3 2015 was Consonance Capital Management, an estimated $17.6M added.
- The largest Vanda Pharmaceuticals seller in Q3 2015 was Goldman Sachs, an estimated $33M sold.
Based on aggregated 13F filings for Q3 2015.